GTCR acquires Czech generics maker Zentiva from Advent International for $4.8 billion

Private equity firm GTCR has struck a 4.1 billion euro ($4.8 billion) deal to buy Czech generic drug maker Zentiva from Advent International, the Financial Times reported on Wednesday, citing unnamed sources. Reuters could not immediately confirm the report. GTCR,…






